Heart, Pain, Stroke, Age related illnesses, Mental Health | September 28, 2014 | Author: The Super Pharmacist
Curcumin is a chemical naturally produced in the rhizome of the turmeric plant, and has been used for centuries in traditional Asian medicine. Turmeric (Curcuma longa) may be familiar as an aromatic, commonly used in Indian cuisine, used to give a distinctive yellow colour to dishes.
Curcumin, a compound known as diferuloyl methane, has been gathering fame over the years for its apparent health-promoting properties. A number of reports and anecdotal evidence claim beneficial effects of curcumin in many health issues, these include:
These are explained by interactions with various biological mechanisms that play a role in both normal biochemical (e.g. immune) functions and disease states. Whether curcumin can truly cure or prevent the conditions with which it has become linked is yet to be confirmed. It has been tested as a therapeutic application in many scientific and clinical studies. These include:
Curcumin has demonstrated the ability to facilitate natural healing through regulation of the biological mechanisms involved in wound repair. This includes tissue growth and structure, and regulating the production of collagen, a protein that forms the basis of scar tissue. It has an established role in the control of infection. Therefore, curcumin is a valid ingredient in novel wound treatments, including dressings, some of which are currently in development.
Alzheimer's disease is a condition in which brain cells are damaged and killed, leading to cognitive decline and the loss of memory in many patients. Cell damage occurs mainly as a result of chemical damage (such as oxidation) and abnormal aggregrates (or plaques) of the protein beta-amyloid, which causes mechanical and further chemical damage to brain cells6. There is evidence that curcumin may alleviate this damage in a number of ways.
Curcumin also demonstrates the ability to significantly increase tumour cell death when combined with the best chemotherapy drug used in pancreatic cancer treatment, gemcitabine, in comparison with untreated controls and gemcitabine alone. The lack of significant clinical activity (beyond the consistent ability to reduce the immune reactions caused by pancreatic cancer) may have been explained by the poor absorption into the system (and thus to its targets, i.e. tumours) from the oral formulation, thus affecting its ability to be effective as a drug.
Curcumin has been linked to the inhibition of tumour growth and the genetic mutations that may lead to cancer.
Pancreatic cancer is a highly malignant and prevalent form of the disease, which responds to the currently approved treatments in less than 10% of cases.
A trial assessing 22 patients receiving 8g oral curcumin a day showed that the chemical elicited a clinical level of reduction in biological markers of cancer, and significant tumour reduction in one of the patients.
This is known as bioavailability. The bioavailability of curcumin is reportedly increased in a new formulation known as Theracumin. A lower dose (30 milligrams) of this was compared to an equal amount of curcumin in human trials. Theracumin demonstrated a 27-fold increase in an important factor of bioavailability in comparison with the original chemical. This formulation is at the stage of clinical development in which safe and effective doses are determined. Currently, it has demonstrated efficacy and a lack of toxicity at higher doses, but has the side-effect of mild diarrhoea. Theracumin may be one of the most promising anti-cancer drugs of the near future.
Curcumin is associated with the control of many natural immune-system molecules that control the inflammatory response, including the 'master control' of inflammation, NF-kappaB (NFkB).
Inflammation is a hallmark of many chronic conditions and disorders, including psoriasis, diabetes, bronchitis, arthritis and cardiovascular disease.
High levels of another pro-inflammatory molecule, C-reactive protein, play a role in the development of heart disease and atherosclerosis. Six trials including 342 human subjects comparing curcumin administration to placebo found that the chemical (or its derivatives) significantly reduced C-reactive protein.
A trial of 67 patients with type 2 diabetes randomised to 150mg curcumin twice daily or conventional treatment found that curcumin significantly reduced inflammatory tissue damage. However, the low bioavailability of curcumin again restricts its use as a therapeutic agent in these conditions. The development of formulations similar to Theracumin may unlock the potential of curcumin as an anti-inflammatory drug.
Diseases of the gastrointestinal tract often involve inflammation or the growth of abnormal and cancer cells. Curcumin may have potential in the treatment of inflammatory bowel disease, mainly through inhibition of NFkB, demonstrated in a number of animal trials. It may alleviate the intestinal ulcers often seen in this condition.
A small-scale trial including ten patients with inflammatory bowel disease found that curcumin appeared to elicit positive effects on disease progression and medication use, but did not report significant results. A larger trial comparing 45 patients taking 2g curcumin daily in addition to their usual medications to 44 continuing normal treatment showed that there was a significant reduction in clinical disease scores in the curcumin group. However, the relapse rates at 12 months for both groups were not significantly different.
Curcumin may prevent the development of gastrointestinal polyps, a precursor of colorectal cancer. A trial of five patients receiving 480mg curcumin three times daily for six months found that polyp size and number were significantly reduced.
Akbik D, Ghadiri M, Chrzanowski W, Rohanizadeh R. Curcumin as a wound healing agent. Life sciences.2014.
Gautam SC, Gao X, Dulchavsky S. Immunomodulation by curcumin. Advances in experimental medicine and biology.2007;595:321-341.
Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. The international journal of biochemistry & cell biology.2009;41(1):40-59.
Fu SZ, Meng XH, Fan J, et al. Acceleration of dermal wound healing by using electrospun curcumin-loaded poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) fibrous mats. Journal of biomedical materials research. Part B, Applied biomaterials.2014;102(3):533-542.
Lv Y, Lei N, Wang D, et al. Protective effect of curcumin against cytomegalovirus infection in Balb/c mice. Environmental toxicology and pharmacology.2014;37(3):1140-1147.
Smith DG, Cappai R, Barnham KJ. The redox chemistry of the Alzheimer's disease amyloid beta peptide. Biochimica et biophysica acta.2007;1768(8):1976-1990.
Kim DS, Park SY, Kim JK. Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from betaA(1-42) insult. Neuroscience letters.2001;303(1):57-61.
Ono K, Hasegawa K, Naiki H, Yamada M. Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. Journal of neuroscience research.2004;75(6):742-750.
Baum L, Ng A. Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. Journal of Alzheimer's disease : JAD.2004;6(4):367-377; discussion 443-369.
Yang F, Lim GP, Begum AN, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. The Journal of biological chemistry.2005;280(7):5892-5901.
Baum L, Lam CW, Cheung SK, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. Journal of clinical psychopharmacology.2008;28(1):110-113.
Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clinical cancer research : an official journal of the American Association for Cancer Research.2008;14(14):4491-4499.
Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer research.2007;67(8):3853-3861.
Sasaki H, Sunagawa Y, Takahashi K, et al. Innovative preparation of curcumin for improved oral bioavailability. Biological & pharmaceutical bulletin.2011;34(5):660-665.
Kanai M, Imaizumi A, Otsuka Y, et al. Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers. Cancer chemotherapy and pharmacology.2012;69(1):65-70.
Basnet P, Skalko-Basnet N. Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules (Basel, Switzerland).2011;16(6):4567-4598.
Sahebkar A. Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytotherapy research : PTR.2014;28(5):633-642.
Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Alternative medicine review : a journal of clinical therapeutic.2009;14(2):141-153.
Kumar S, Ahuja V, Sankar MJ, Kumar A, Moss AC. Curcumin for maintenance of remission in ulcerative colitis. The Cochrane database of systematic reviews.2012;10:Cd008424.
Cruz-Correa M, Shoskes DA, Sanchez P, et al. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.2006;4(8):1035-1038.